Search

By Industry Solutions (1)
By Phase (1)
By Therapeutic Area (2)
Keywords (10)

Filters

Showing results 1 - 16 of 399 for .

Showing results 1 - 16 of 399 for .

Cardiovascular Disease Drug Development | Covance
At Covance, our dedicated cardiovascular specialists have a unique combination of both academic and industry experience that provides you with insightful study design, predictive study management and operational service excellence. Maximize your cardiovascular drug development program with Covance's experience and cross-functional solutions.
Orphan Drug Development for Rare Diseases | Covance
Covance helps rare disease and orphan drug companies find and identify specific rare disease patients to meet challenging orphan drug recruitment goals and run rare disease clinical trials. With Covance, you’ll access a combination of dedicated rare disease therapeutic area expertise alongside comprehensive operational support to assist with every aspect of your orphan drug clinical study.
Phase IIb Clinical Trials/Phase III Clinical Trials
As you move to high stakes phase IIb clinical trials and phase III clinical development, you’ll benefit from our end-to-end suite of services.
Immunology & Immunotherapeutic Drugs | Covance
Covance Immunogology services. A fully integrated immunotherapeutic drug development capability for better ROI.
Rare Diseases Drug Development Solutions and Clinical Trials | Covance
Covance combines extensive rare disease clinical trial experience with actionable, patient-centric approaches to address high unmet medical needs
Market Access Consulting | Drug Commercialization | Covance
Covance delivers market access consulting designed to explore your product's potential.
Patient and Provider Services | Drug Development | Covance
Working together, we will remove barriers, build relationships and gain insights as your product reaches the real world of patients and providers.
Canines Research Models | Covance
Our canine acclimation services, developed under the guidance of a canine behaviorist, reduce the time, labor and cost of bringing animals onto your study.
Nonhuman Primates Research Models | Covance
With more than 200 acres of secure quarantine, breeding and holding space for nonhuman primate research models, ours is the largest of its kind in the US.
Rabbits Research Models | Covance
Covance is one of the world’s largest providers of Specific Pathogen Free rabbits for use in basic research and nonclinical drug discovery and development.
Surgical & Technical Services for Research Models | Covance
In-house veterinarians oversee all procedures performed by AALAS certified technicians in our dedicated AAALAC International Accredited facilities.
Proof of Concept Study in Clinical Research - PoC® Services | Covance
Bring together your clinical and economic proof of concept study (PoC®) to maximize the value of your molecule to get your drug developed to market.
Drug Abuse Potential - A Data Analysis Strategy for Nonclinical Self-Administration
If a drug compound (or its metabolites) crosses the blood-brain barrier, then the FDA requires an Abuse Potential Assessment, which includes GLP self-administration, drug discrimination and physical dependency studies. For some drug classes like stimulants (i.e. amphetamine and cocaine), self-administration studies have been widely characterized in several species with the corresponding data analysis being fairly straightforward. For other drug classes, however, such as sedatives (i.e....
Designing a Comprehensive Self-Administration Drug Abuse Liability Study
The self-administration study assesses the potential of a drug to maintain lever-pressing behavior due to its positive reinforcing effects. According to the 2017 FDA Guidance for Industry Assessment, "if animals actively work at a behavioral task to receive a dose of the drug, it is likely that the drug will [also] be rewarding in humans." This article provides an overview of how Covance designs a typical self-administration study to meet regulatory requirements and advances a sponsor's...
Immune Checkpoint Inhibitors Induce Differential Anti-Tumor Response and Immune Cell Infiltration Across Mouse Allograft Tumor Models
SITC 2018 -- Clinical success of immune checkpoint inhibitors has accelerated the evaluation of immune-related targets for novel anti-cancer therapies. Preclinical testing of immune-targeted oncology agents requires preclinical models with functional immune systems. Utilization of murine syngeneic tumor models provides a robust system to evaluate both anti-tumor activity and mechanism of action of novel therapeutics. This study evaluates the efficacy and anti-tumor immune response of...
Sampling of Neural Tissues in Preclinical Toxicity Studies
National AALAS 2018 -- Recently, there has been an increase in preclinical safety evaluation and toxicity studies with compounds indicated to treat neurological disorders or those suspected to cause neural toxicity. This surge in collection of specialized neural tissue is likely due to the recent Society of Toxicologic Pathology (STP) publication "Recommended Best Practices for Sampling, Processing, and Analysis of the Peripheral Nervous System (Nerves and Somatic and Autonomic Ganglia)...